drugset / Trial / NCT05848999
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of UCLM802 (Anti-Mesothelin CAR-T) cell injection in patients with Mesothelin-positive advanced malignant solid tumors.
Timeline
- Start
- 2023-04-27
- Primary completion
- 2025-05
- Completion
- 2025-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UCLM802 | Unknown | 100000 cells/kg | Intravenous |
| Subject | UCLM802 | Unknown | 2e+06 cells/kg | Intravenous |